Global Personalized Cancer Medicine Market by Application (Bone Cancer, Blood Cancer, Breast Cancer, Prostate Cancer, Intestinal Cancer, Skin Cancer, Respiratory/Lung cancer), by Technology (ImmunohistochemistryIn Situ Hybridization (Immunohistochemistry, In Situ Hybridization ISH), by End User (Research Laboratories, Hospitals), by Product Type (Pharmaceutical, Medical Devices, Genomic Medicine, Esoteric Lab Tests, Genetic Testing, Complementary & Alternative Medicine, Esoteric Lab Services, Telemedicine, DTC Diagnostics, Health Information Technology, Retail Nutrition) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Personalized Cancer Medicine Market research report which is segmented by Application (Bone Cancer, Blood Cancer, Breast Cancer, Prostate Cancer, Intestinal Cancer, Skin Cancer, Respiratory/Lung cancer), by Technology (ImmunohistochemistryIn Situ Hybridization (Immunohistochemistry, In Situ Hybridization ISH), by End User (Research Laboratories, Hospitals), by Product Type (Pharmaceutical, Medical Devices, Genomic Medicine, Esoteric Lab Tests, Genetic Testing, Complementary & Alternative Medicine, Esoteric Lab Services, Telemedicine, DTC Diagnostics, Health Information Technology, Retail Nutrition), By Players/Companies AstraZeneca, Cepheid, Roche, Glaxosmithkline Plc (GSK), Bristol-Myers Squibb Myriad Genetics and Foundation Medicine., Abbott, Novartis, Thermo Fisher Scientific, bioMérieux, Qiagen, Pfizer, Cancer Genetics, LABORATORY CORPORATION OF AMERICA HOLDINGS, Quest Diagnostics, Medtronic, Eli Lilly & Company”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Personalized Cancer Medicine Market Research Report |
| By Application | Bone Cancer, Blood Cancer, Breast Cancer, Prostate Cancer, Intestinal Cancer, Skin Cancer, Respiratory/Lung cancer |
| By Technology (ImmunohistochemistryIn Situ Hybridization | Immunohistochemistry, In Situ Hybridization ISH |
| By End User | Research Laboratories, Hospitals |
| By Product Type | Pharmaceutical, Medical Devices, Genomic Medicine, Esoteric Lab Tests, Genetic Testing, Complementary & Alternative Medicine, Esoteric Lab Services, Telemedicine, DTC Diagnostics, Health Information Technology, Retail Nutrition |
| By Companies | AstraZeneca, Cepheid, Roche, Glaxosmithkline Plc (GSK), Bristol-Myers Squibb Myriad Genetics and Foundation Medicine., Abbott, Novartis, Thermo Fisher Scientific, bioMérieux, Qiagen, Pfizer, Cancer Genetics, LABORATORY CORPORATION OF AMERICA HOLDINGS, Quest Diagnostics, Medtronic, Eli Lilly & Company |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 243 |
| Number of Tables & Figures | 171 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Personalized Cancer Medicine Market Report Segments:
The market is segmented by Application (Bone Cancer, Blood Cancer, Breast Cancer, Prostate Cancer, Intestinal Cancer, Skin Cancer, Respiratory/Lung cancer), by Technology (ImmunohistochemistryIn Situ Hybridization (Immunohistochemistry, In Situ Hybridization ISH), by End User (Research Laboratories, Hospitals), by Product Type (Pharmaceutical, Medical Devices, Genomic Medicine, Esoteric Lab Tests, Genetic Testing, Complementary & Alternative Medicine, Esoteric Lab Services, Telemedicine, DTC Diagnostics, Health Information Technology, Retail Nutrition).
Some of the companies that are profiled in this report are:
- AstraZeneca
- Cepheid
- Roche
- Glaxosmithkline Plc (GSK)
- Bristol-Myers Squibb Myriad Genetics and Foundation Medicine.
- Abbott
- Novartis
- Thermo Fisher Scientific
- bioMérieux
- Qiagen
- Pfizer
- Cancer Genetics
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- Quest Diagnostics
- Medtronic
- Eli Lilly & Company
Personalized Cancer Medicine Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Personalized Cancer Medicine Market
Overview of the regional outlook of the Personalized Cancer Medicine Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Personalized Cancer Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Personalized Cancer Medicine Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Bone Cancer
2. Blood Cancer
3. Breast Cancer
4. Prostate Cancer
5. Intestinal Cancer
6. Skin Cancer
7. Respiratory/Lung cancer
7. By Technology (ImmunohistochemistryIn Situ Hybridization:1. Immunohistochemistry
2. In Situ Hybridization ISH
8. By End User:1. Research Laboratories
2. Hospitals
9. By Product Type:1. Pharmaceutical
2. Medical Devices
3. Genomic Medicine
4. Esoteric Lab Tests
5. Genetic Testing
6. Complementary & Alternative Medicine
7. Esoteric Lab Services
8. Telemedicine
9. DTC Diagnostics
10. Health Information Technology
11. Retail Nutrition
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Personalized Cancer Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Personalized Cancer Medicine Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Personalized Cancer Medicine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Personalized Cancer Medicine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Personalized Cancer Medicine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Personalized Cancer Medicine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Personalized Cancer Medicine Market Size & Forecast, 2018-2028
4.5.1 Personalized Cancer Medicine Market Size and Y-o-Y Growth
4.5.2 Personalized Cancer Medicine Market Absolute $ Opportunity
Chapter 5 Global Personalized Cancer Medicine Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 Personalized Cancer Medicine Market Size Forecast by Application
5.2.1 Bone Cancer
5.2.2 Blood Cancer
5.2.3 Breast Cancer
5.2.4 Prostate Cancer
5.2.5 Intestinal Cancer
5.2.6 Skin Cancer
5.2.7 Respiratory/Lung cancer
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global Personalized Cancer Medicine Market Analysis and Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology (ImmunohistochemistryIn Situ Hybridization
6.1.2 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
6.1.3 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
6.2 Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
6.2.1 Immunohistochemistry
6.2.2 In Situ Hybridization ISH
6.3 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
Chapter 7 Global Personalized Cancer Medicine Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Personalized Cancer Medicine Market Size Forecast by End User
7.2.1 Research Laboratories
7.2.2 Hospitals
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Personalized Cancer Medicine Market Analysis and Forecast by Product Type
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product Type
8.1.2 Basis Point Share (BPS) Analysis by Product Type
8.1.3 Absolute $ Opportunity Assessment by Product Type
8.2 Personalized Cancer Medicine Market Size Forecast by Product Type
8.2.1 Pharmaceutical
8.2.2 Medical Devices
8.2.3 Genomic Medicine
8.2.4 Esoteric Lab Tests
8.2.5 Genetic Testing
8.2.6 Complementary & Alternative Medicine
8.2.7 Esoteric Lab Services
8.2.8 Telemedicine
8.2.9 DTC Diagnostics
8.2.10 Health Information Technology
8.2.11 Retail Nutrition
8.3 Market Attractiveness Analysis by Product Type
Chapter 9 Global Personalized Cancer Medicine Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Personalized Cancer Medicine Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Personalized Cancer Medicine Analysis and Forecast
11.1 Introduction
11.2 North America Personalized Cancer Medicine Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Personalized Cancer Medicine Market Size Forecast by Application
11.6.1 Bone Cancer
11.6.2 Blood Cancer
11.6.3 Breast Cancer
11.6.4 Prostate Cancer
11.6.5 Intestinal Cancer
11.6.6 Skin Cancer
11.6.7 Respiratory/Lung cancer
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 North America Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
11.10.1 Immunohistochemistry
11.10.2 In Situ Hybridization ISH
11.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
11.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
11.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
11.14 North America Personalized Cancer Medicine Market Size Forecast by End User
11.14.1 Research Laboratories
11.14.2 Hospitals
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
11.18 North America Personalized Cancer Medicine Market Size Forecast by Product Type
11.18.1 Pharmaceutical
11.18.2 Medical Devices
11.18.3 Genomic Medicine
11.18.4 Esoteric Lab Tests
11.18.5 Genetic Testing
11.18.6 Complementary & Alternative Medicine
11.18.7 Esoteric Lab Services
11.18.8 Telemedicine
11.18.9 DTC Diagnostics
11.18.10 Health Information Technology
11.18.11 Retail Nutrition
11.19 Basis Point Share (BPS) Analysis by Product Type
11.20 Absolute $ Opportunity Assessment by Product Type
11.21 Market Attractiveness Analysis by Product Type
Chapter 12 Europe Personalized Cancer Medicine Analysis and Forecast
12.1 Introduction
12.2 Europe Personalized Cancer Medicine Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Personalized Cancer Medicine Market Size Forecast by Application
12.6.1 Bone Cancer
12.6.2 Blood Cancer
12.6.3 Breast Cancer
12.6.4 Prostate Cancer
12.6.5 Intestinal Cancer
12.6.6 Skin Cancer
12.6.7 Respiratory/Lung cancer
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Europe Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
12.10.1 Immunohistochemistry
12.10.2 In Situ Hybridization ISH
12.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
12.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
12.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
12.14 Europe Personalized Cancer Medicine Market Size Forecast by End User
12.14.1 Research Laboratories
12.14.2 Hospitals
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
12.18 Europe Personalized Cancer Medicine Market Size Forecast by Product Type
12.18.1 Pharmaceutical
12.18.2 Medical Devices
12.18.3 Genomic Medicine
12.18.4 Esoteric Lab Tests
12.18.5 Genetic Testing
12.18.6 Complementary & Alternative Medicine
12.18.7 Esoteric Lab Services
12.18.8 Telemedicine
12.18.9 DTC Diagnostics
12.18.10 Health Information Technology
12.18.11 Retail Nutrition
12.19 Basis Point Share (BPS) Analysis by Product Type
12.20 Absolute $ Opportunity Assessment by Product Type
12.21 Market Attractiveness Analysis by Product Type
Chapter 13 Asia Pacific Personalized Cancer Medicine Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Application
13.6.1 Bone Cancer
13.6.2 Blood Cancer
13.6.3 Breast Cancer
13.6.4 Prostate Cancer
13.6.5 Intestinal Cancer
13.6.6 Skin Cancer
13.6.7 Respiratory/Lung cancer
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
13.10.1 Immunohistochemistry
13.10.2 In Situ Hybridization ISH
13.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
13.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
13.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
13.14 Asia Pacific Personalized Cancer Medicine Market Size Forecast by End User
13.14.1 Research Laboratories
13.14.2 Hospitals
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
13.18 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Product Type
13.18.1 Pharmaceutical
13.18.2 Medical Devices
13.18.3 Genomic Medicine
13.18.4 Esoteric Lab Tests
13.18.5 Genetic Testing
13.18.6 Complementary & Alternative Medicine
13.18.7 Esoteric Lab Services
13.18.8 Telemedicine
13.18.9 DTC Diagnostics
13.18.10 Health Information Technology
13.18.11 Retail Nutrition
13.19 Basis Point Share (BPS) Analysis by Product Type
13.20 Absolute $ Opportunity Assessment by Product Type
13.21 Market Attractiveness Analysis by Product Type
Chapter 14 Latin America Personalized Cancer Medicine Analysis and Forecast
14.1 Introduction
14.2 Latin America Personalized Cancer Medicine Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Personalized Cancer Medicine Market Size Forecast by Application
14.6.1 Bone Cancer
14.6.2 Blood Cancer
14.6.3 Breast Cancer
14.6.4 Prostate Cancer
14.6.5 Intestinal Cancer
14.6.6 Skin Cancer
14.6.7 Respiratory/Lung cancer
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Latin America Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
14.10.1 Immunohistochemistry
14.10.2 In Situ Hybridization ISH
14.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
14.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
14.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
14.14 Latin America Personalized Cancer Medicine Market Size Forecast by End User
14.14.1 Research Laboratories
14.14.2 Hospitals
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
14.18 Latin America Personalized Cancer Medicine Market Size Forecast by Product Type
14.18.1 Pharmaceutical
14.18.2 Medical Devices
14.18.3 Genomic Medicine
14.18.4 Esoteric Lab Tests
14.18.5 Genetic Testing
14.18.6 Complementary & Alternative Medicine
14.18.7 Esoteric Lab Services
14.18.8 Telemedicine
14.18.9 DTC Diagnostics
14.18.10 Health Information Technology
14.18.11 Retail Nutrition
14.19 Basis Point Share (BPS) Analysis by Product Type
14.20 Absolute $ Opportunity Assessment by Product Type
14.21 Market Attractiveness Analysis by Product Type
Chapter 15 Middle East & Africa (MEA) Personalized Cancer Medicine Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Application
15.6.1 Bone Cancer
15.6.2 Blood Cancer
15.6.3 Breast Cancer
15.6.4 Prostate Cancer
15.6.5 Intestinal Cancer
15.6.6 Skin Cancer
15.6.7 Respiratory/Lung cancer
15.7 Basis Point Share (BPS) Analysis by Application
15.8 Absolute $ Opportunity Assessment by Application
15.9 Market Attractiveness Analysis by Application
15.10 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
15.10.1 Immunohistochemistry
15.10.2 In Situ Hybridization ISH
15.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
15.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
15.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
15.14 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by End User
15.14.1 Research Laboratories
15.14.2 Hospitals
15.15 Basis Point Share (BPS) Analysis by End User
15.16 Absolute $ Opportunity Assessment by End User
15.17 Market Attractiveness Analysis by End User
15.18 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Product Type
15.18.1 Pharmaceutical
15.18.2 Medical Devices
15.18.3 Genomic Medicine
15.18.4 Esoteric Lab Tests
15.18.5 Genetic Testing
15.18.6 Complementary & Alternative Medicine
15.18.7 Esoteric Lab Services
15.18.8 Telemedicine
15.18.9 DTC Diagnostics
15.18.10 Health Information Technology
15.18.11 Retail Nutrition
15.19 Basis Point Share (BPS) Analysis by Product Type
15.20 Absolute $ Opportunity Assessment by Product Type
15.21 Market Attractiveness Analysis by Product Type
Chapter 16 Competition Landscape
16.1 Personalized Cancer Medicine Market: Competitive Dashboard
16.2 Global Personalized Cancer Medicine Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 AstraZeneca
16.3.2 Cepheid
16.3.3 Roche
16.3.4 Glaxosmithkline Plc (GSK)
16.3.5 Bristol-Myers Squibb Myriad Genetics and Foundation Medicine.
16.3.6 Abbott
16.3.7 Novartis
16.3.8 Thermo Fisher Scientific
16.3.9 bioMérieux
16.3.10 Qiagen
16.3.11 Pfizer
16.3.12 Cancer Genetics
16.3.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
16.3.14 Quest Diagnostics
16.3.15 Medtronic
16.3.16 Eli Lilly & Company
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Personalized Cancer Medicine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Personalized Cancer Medicine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Personalized Cancer Medicine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Personalized Cancer Medicine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Personalized Cancer Medicine Market Size & Forecast, 2018-2028
4.5.1 Personalized Cancer Medicine Market Size and Y-o-Y Growth
4.5.2 Personalized Cancer Medicine Market Absolute $ Opportunity
Chapter 5 Global Personalized Cancer Medicine Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 Personalized Cancer Medicine Market Size Forecast by Application
5.2.1 Bone Cancer
5.2.2 Blood Cancer
5.2.3 Breast Cancer
5.2.4 Prostate Cancer
5.2.5 Intestinal Cancer
5.2.6 Skin Cancer
5.2.7 Respiratory/Lung cancer
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global Personalized Cancer Medicine Market Analysis and Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology (ImmunohistochemistryIn Situ Hybridization
6.1.2 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
6.1.3 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
6.2 Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
6.2.1 Immunohistochemistry
6.2.2 In Situ Hybridization ISH
6.3 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
Chapter 7 Global Personalized Cancer Medicine Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Personalized Cancer Medicine Market Size Forecast by End User
7.2.1 Research Laboratories
7.2.2 Hospitals
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Personalized Cancer Medicine Market Analysis and Forecast by Product Type
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product Type
8.1.2 Basis Point Share (BPS) Analysis by Product Type
8.1.3 Absolute $ Opportunity Assessment by Product Type
8.2 Personalized Cancer Medicine Market Size Forecast by Product Type
8.2.1 Pharmaceutical
8.2.2 Medical Devices
8.2.3 Genomic Medicine
8.2.4 Esoteric Lab Tests
8.2.5 Genetic Testing
8.2.6 Complementary & Alternative Medicine
8.2.7 Esoteric Lab Services
8.2.8 Telemedicine
8.2.9 DTC Diagnostics
8.2.10 Health Information Technology
8.2.11 Retail Nutrition
8.3 Market Attractiveness Analysis by Product Type
Chapter 9 Global Personalized Cancer Medicine Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Personalized Cancer Medicine Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Personalized Cancer Medicine Analysis and Forecast
11.1 Introduction
11.2 North America Personalized Cancer Medicine Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Personalized Cancer Medicine Market Size Forecast by Application
11.6.1 Bone Cancer
11.6.2 Blood Cancer
11.6.3 Breast Cancer
11.6.4 Prostate Cancer
11.6.5 Intestinal Cancer
11.6.6 Skin Cancer
11.6.7 Respiratory/Lung cancer
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 North America Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
11.10.1 Immunohistochemistry
11.10.2 In Situ Hybridization ISH
11.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
11.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
11.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
11.14 North America Personalized Cancer Medicine Market Size Forecast by End User
11.14.1 Research Laboratories
11.14.2 Hospitals
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
11.18 North America Personalized Cancer Medicine Market Size Forecast by Product Type
11.18.1 Pharmaceutical
11.18.2 Medical Devices
11.18.3 Genomic Medicine
11.18.4 Esoteric Lab Tests
11.18.5 Genetic Testing
11.18.6 Complementary & Alternative Medicine
11.18.7 Esoteric Lab Services
11.18.8 Telemedicine
11.18.9 DTC Diagnostics
11.18.10 Health Information Technology
11.18.11 Retail Nutrition
11.19 Basis Point Share (BPS) Analysis by Product Type
11.20 Absolute $ Opportunity Assessment by Product Type
11.21 Market Attractiveness Analysis by Product Type
Chapter 12 Europe Personalized Cancer Medicine Analysis and Forecast
12.1 Introduction
12.2 Europe Personalized Cancer Medicine Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Personalized Cancer Medicine Market Size Forecast by Application
12.6.1 Bone Cancer
12.6.2 Blood Cancer
12.6.3 Breast Cancer
12.6.4 Prostate Cancer
12.6.5 Intestinal Cancer
12.6.6 Skin Cancer
12.6.7 Respiratory/Lung cancer
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Europe Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
12.10.1 Immunohistochemistry
12.10.2 In Situ Hybridization ISH
12.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
12.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
12.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
12.14 Europe Personalized Cancer Medicine Market Size Forecast by End User
12.14.1 Research Laboratories
12.14.2 Hospitals
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
12.18 Europe Personalized Cancer Medicine Market Size Forecast by Product Type
12.18.1 Pharmaceutical
12.18.2 Medical Devices
12.18.3 Genomic Medicine
12.18.4 Esoteric Lab Tests
12.18.5 Genetic Testing
12.18.6 Complementary & Alternative Medicine
12.18.7 Esoteric Lab Services
12.18.8 Telemedicine
12.18.9 DTC Diagnostics
12.18.10 Health Information Technology
12.18.11 Retail Nutrition
12.19 Basis Point Share (BPS) Analysis by Product Type
12.20 Absolute $ Opportunity Assessment by Product Type
12.21 Market Attractiveness Analysis by Product Type
Chapter 13 Asia Pacific Personalized Cancer Medicine Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Application
13.6.1 Bone Cancer
13.6.2 Blood Cancer
13.6.3 Breast Cancer
13.6.4 Prostate Cancer
13.6.5 Intestinal Cancer
13.6.6 Skin Cancer
13.6.7 Respiratory/Lung cancer
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
13.10.1 Immunohistochemistry
13.10.2 In Situ Hybridization ISH
13.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
13.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
13.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
13.14 Asia Pacific Personalized Cancer Medicine Market Size Forecast by End User
13.14.1 Research Laboratories
13.14.2 Hospitals
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
13.18 Asia Pacific Personalized Cancer Medicine Market Size Forecast by Product Type
13.18.1 Pharmaceutical
13.18.2 Medical Devices
13.18.3 Genomic Medicine
13.18.4 Esoteric Lab Tests
13.18.5 Genetic Testing
13.18.6 Complementary & Alternative Medicine
13.18.7 Esoteric Lab Services
13.18.8 Telemedicine
13.18.9 DTC Diagnostics
13.18.10 Health Information Technology
13.18.11 Retail Nutrition
13.19 Basis Point Share (BPS) Analysis by Product Type
13.20 Absolute $ Opportunity Assessment by Product Type
13.21 Market Attractiveness Analysis by Product Type
Chapter 14 Latin America Personalized Cancer Medicine Analysis and Forecast
14.1 Introduction
14.2 Latin America Personalized Cancer Medicine Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Personalized Cancer Medicine Market Size Forecast by Application
14.6.1 Bone Cancer
14.6.2 Blood Cancer
14.6.3 Breast Cancer
14.6.4 Prostate Cancer
14.6.5 Intestinal Cancer
14.6.6 Skin Cancer
14.6.7 Respiratory/Lung cancer
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Latin America Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
14.10.1 Immunohistochemistry
14.10.2 In Situ Hybridization ISH
14.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
14.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
14.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
14.14 Latin America Personalized Cancer Medicine Market Size Forecast by End User
14.14.1 Research Laboratories
14.14.2 Hospitals
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
14.18 Latin America Personalized Cancer Medicine Market Size Forecast by Product Type
14.18.1 Pharmaceutical
14.18.2 Medical Devices
14.18.3 Genomic Medicine
14.18.4 Esoteric Lab Tests
14.18.5 Genetic Testing
14.18.6 Complementary & Alternative Medicine
14.18.7 Esoteric Lab Services
14.18.8 Telemedicine
14.18.9 DTC Diagnostics
14.18.10 Health Information Technology
14.18.11 Retail Nutrition
14.19 Basis Point Share (BPS) Analysis by Product Type
14.20 Absolute $ Opportunity Assessment by Product Type
14.21 Market Attractiveness Analysis by Product Type
Chapter 15 Middle East & Africa (MEA) Personalized Cancer Medicine Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Application
15.6.1 Bone Cancer
15.6.2 Blood Cancer
15.6.3 Breast Cancer
15.6.4 Prostate Cancer
15.6.5 Intestinal Cancer
15.6.6 Skin Cancer
15.6.7 Respiratory/Lung cancer
15.7 Basis Point Share (BPS) Analysis by Application
15.8 Absolute $ Opportunity Assessment by Application
15.9 Market Attractiveness Analysis by Application
15.10 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Technology (ImmunohistochemistryIn Situ Hybridization
15.10.1 Immunohistochemistry
15.10.2 In Situ Hybridization ISH
15.11 Basis Point Share (BPS) Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
15.12 Absolute $ Opportunity Assessment by Technology (ImmunohistochemistryIn Situ Hybridization
15.13 Market Attractiveness Analysis by Technology (ImmunohistochemistryIn Situ Hybridization
15.14 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by End User
15.14.1 Research Laboratories
15.14.2 Hospitals
15.15 Basis Point Share (BPS) Analysis by End User
15.16 Absolute $ Opportunity Assessment by End User
15.17 Market Attractiveness Analysis by End User
15.18 Middle East & Africa (MEA) Personalized Cancer Medicine Market Size Forecast by Product Type
15.18.1 Pharmaceutical
15.18.2 Medical Devices
15.18.3 Genomic Medicine
15.18.4 Esoteric Lab Tests
15.18.5 Genetic Testing
15.18.6 Complementary & Alternative Medicine
15.18.7 Esoteric Lab Services
15.18.8 Telemedicine
15.18.9 DTC Diagnostics
15.18.10 Health Information Technology
15.18.11 Retail Nutrition
15.19 Basis Point Share (BPS) Analysis by Product Type
15.20 Absolute $ Opportunity Assessment by Product Type
15.21 Market Attractiveness Analysis by Product Type
Chapter 16 Competition Landscape
16.1 Personalized Cancer Medicine Market: Competitive Dashboard
16.2 Global Personalized Cancer Medicine Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 AstraZeneca
16.3.2 Cepheid
16.3.3 Roche
16.3.4 Glaxosmithkline Plc (GSK)
16.3.5 Bristol-Myers Squibb Myriad Genetics and Foundation Medicine.
16.3.6 Abbott
16.3.7 Novartis
16.3.8 Thermo Fisher Scientific
16.3.9 bioMérieux
16.3.10 Qiagen
16.3.11 Pfizer
16.3.12 Cancer Genetics
16.3.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
16.3.14 Quest Diagnostics
16.3.15 Medtronic
16.3.16 Eli Lilly & Company
Segments Covered in the Report
The global Personalized Cancer Medicine market has been segmented based on
By Application
The global Personalized Cancer Medicine market has been segmented based on
By Application
- Bone Cancer
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Intestinal Cancer
- Skin Cancer
- Respiratory/Lung cancer
- Immunohistochemistry
- In Situ Hybridization ISH
- Research Laboratories
- Hospitals
- Pharmaceutical
- Medical Devices
- Genomic Medicine
- Esoteric Lab Tests
- Genetic Testing
- Complementary & Alternative Medicine
- Esoteric Lab Services
- Telemedicine
- DTC Diagnostics
- Health Information Technology
- Retail Nutrition
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- AstraZeneca
- Cepheid
- Roche
- Glaxosmithkline Plc (GSK)
- Bristol-Myers Squibb Myriad Genetics and Foundation Medicine.
- Abbott
- Novartis
- Thermo Fisher Scientific
- bioMérieux
- Qiagen
- Pfizer
- Cancer Genetics
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- Quest Diagnostics
- Medtronic
- Eli Lilly & Company
Our Clients
Related Reports
Some other reports from this category!
